Esengul Kocak Uzel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Esengul Kocak Uzel has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Metin Figen
Department of Radiation Oncology, Health Sciences University Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Bakirkoy, Istanbul, Turkey
6 shared publications - Meltem Kirli Bolukbas
Department of Radiation Oncology, Health Sciences University Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey
5 shared publications - Gülşen Pınar Soydemir
Department of Radiation Oncology, Health Sciences University Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Bakirkoy, Istanbul, Turkey
3 shared publications - Melisa Bagci
Department of Radiation Oncology, Marmara University Medical School, Istanbul, Turkey
3 shared publications Metin Figen
Univ Hlth Sci Turkiye, Bakirkoy Dr Sadi Konuk Training & Res Hosp, Clin Radiat Oncol, Istanbul, Turkiye
3 shared publications- Olgun Elicin
Department of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland
2 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Outcomes of hypofractionated stereotactic radiotherapy for brain metastases: do we treat patients or lesions?
- 3 June 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessOutcomes of hypofractionated stereotactic radiotherapy for brain metastases: do we treat patients or lesions?
- Open Access
- 16 February 2026
- Published by Springer Nature in Radiation Oncology
- Vol. 21 (1)
A practical non-custom abdominal corset-based approach for diaphragm motion management in stereotactic body radiotherapy
In Stereotactic body radiation therapy (SBRT), abdominal compression devices are commonly used to manage respiratory motion. The high cost, bulky design, a
- 16 February 2026
- Published by Springer Nature in Radiation Oncology
- Vol. 21 (1)
Open AccessA practical non-custom abdominal corset-based approach for diaphragm motion management in stereotactic body radiotherapy
In Stereotactic body radiation therapy (SBRT), abdominal compression devices are commonly used to manage respiratory motion. The high cost, bulky design, a
- Open Access
- 20 December 2024
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-8
Cancer awareness across borders: a comparative study of internet search trends for breast and prostate cancer in Europe and Turkey
The governments and private organizations strongly support cancer awareness campaigns. It remains unknown whether the campaigns during the awareness months have the same effect in every country. This study aims to compare the impact of awareness campaigns conducted in October for breast cancer and September for prostate cancer on internet search trends among the most populous European countries and Turkey. The research is framed within the context of comparing awareness campaign effects between countries for the first time. Utilizing Google Trends data from 2018 to 2022, we collected search term data for breast and prostate cancer in Germany, France, the United Kingdom, Italy, Spain, and Turkey. Search volumes were standardized based on each country’s population and internet user rates. Multivariate analysis of variance (MANOVA) was conducted to assess the influence of awareness campaigns on internet search volumes. The MANOVA results indicated that the awareness campaigns had a significant impact on internet search volumes for breast and prostate cancer. The campaigns were found to be statistically significant in Italy, France, United Kingdom for breast cancer. And also, the internet search volumes of Italy, France, and Germany increased statistically significant for prostate cancer. The internet search data of Turkey, Germany, France, the United Kingdom, Italy, and Spain were analyzed, revealing that both Italy and France responded positively to awareness campaigns for both breast and prostate cancer, resulting in increased awareness. These findings can serve as a guiding framework for developing effective strategies to enhance cancer awareness.
- 20 December 2024
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-8
Open AccessCancer awareness across borders: a comparative study of internet search trends for breast and prostate cancer in Europe and Turkey
The governments and private organizations strongly support cancer awareness campaigns. It remains unknown whether the campaigns during the awareness months have the same effect in every country. This study aims to compare the impact of awareness campaigns conducted in October for breast cancer and September for prostate cancer on internet search trends among the most populous European countries and Turkey. The research is framed within the context of comparing awareness campaign effects between countries for the first time. Utilizing Google Trends data from 2018 to 2022, we collected search term data for breast and prostate cancer in Germany, France, the United Kingdom, Italy, Spain, and Turkey. Search volumes were standardized based on each country’s population and internet user rates. Multivariate analysis of variance (MANOVA) was conducted to assess the influence of awareness campaigns on internet search volumes. The MANOVA results indicated that the awareness campaigns had a significant impact on internet search volumes for breast and prostate cancer. The campaigns were found to be statistically significant in Italy, France, United Kingdom for breast cancer. And also, the internet search volumes of Italy, France, and Germany increased statistically significant for prostate cancer. The internet search data of Turkey, Germany, France, the United Kingdom, Italy, and Spain were analyzed, revealing that both Italy and France responded positively to awareness campaigns for both breast and prostate cancer, resulting in increased awareness. These findings can serve as a guiding framework for developing effective strategies to enhance cancer awareness.
- 18 September 2024
- Published by Galenos Yayinevi in Medical Journal of Bakırkoy
- Vol. 20 (3) , 232-237
Stereotactic Body Radiation Therapy For Medically Inoperable Stage I Non-small Cell Lung Cancer
Stereotactic Body Radiation Therapy For Medically Inoperable Stage I Non-small Cell Lung Cancer - Medical Journal of Bakirkoy
- 18 September 2024
- Published by Galenos Yayinevi in Medical Journal of Bakırkoy
- Vol. 20 (3) , 232-237
Stereotactic Body Radiation Therapy For Medically Inoperable Stage I Non-small Cell Lung Cancer
Stereotactic Body Radiation Therapy For Medically Inoperable Stage I Non-small Cell Lung Cancer - Medical Journal of Bakirkoy
- Open Access
- 9 November 2023
- Published by Springer Nature in European Journal of Medical Research
- Vol. 28 (1) , 1-9
Cardiac protective techniques in left breast radiotherapy: rapid selection criteria for routine clinical decision making
In left breast radiotherapy (RT) desired heart doses may be achieved without heart-sparing RT techniques in some patients. We aimed to examine the existence of predictive factors and cutoff points to determine which patients are the main candidates for heart-sparing RT techniques. Dosimetric data for left breast cancer was examined. RT plans were made at conventional doses to the breast and peripheral lymph nodes. Statistical analyses were performed using SPSS 22.0 (SPSS Inc., IBM Corp., Armonk, NY). 114 cases were evaluated by ROC (Receiver operating characteristic) analysis in the breast-conserving surgery (BCS) and mastectomy groups. While only left lung volume (AUC: 0.74, 95% CI 0.61–0.87, p = 0.002) was significant in BCS cases, in cases with mastectomy, left lung volume (AUC: 0.81, 95% CI 0.69–0.94, p = 0.002) and lung/heart volume ratio (AUC: 0.83, 95% CI 0.70–0.96, p = 0.001) had a significant relationship with the relevance of heart doses. The cutoff point of 1.92 was selected for the lung/heart volume ratio for the mastectomized patients. Moreover, the cutoff point 1154 cc and 1208 cc was determined for the left lung volume for the BCS and mastectomized patients, respectively. Various cutoff points in left breast RT can be used to predict whether RT plans will meet QUANTEC (Quantitative Analysis of Normal Tissue Effects in the Clinic) heart dose limits. Evaluating only these few cutoff points before planning makes it possible to eliminate 70% of patients with BCS and 40% of patients with mastectomy from respiratory-controlled methods, which require time and effort. Patients with lung volume and lung/heart volume ratio smaller than the cutoff values can be considered primary candidates for heart-sparing techniques.
- 9 November 2023
- Published by Springer Nature in European Journal of Medical Research
- Vol. 28 (1) , 1-9
Open AccessCardiac protective techniques in left breast radiotherapy: rapid selection criteria for routine clinical decision making
In left breast radiotherapy (RT) desired heart doses may be achieved without heart-sparing RT techniques in some patients. We aimed to examine the existence of predictive factors and cutoff points to determine which patients are the main candidates for heart-sparing RT techniques. Dosimetric data for left breast cancer was examined. RT plans were made at conventional doses to the breast and peripheral lymph nodes. Statistical analyses were performed using SPSS 22.0 (SPSS Inc., IBM Corp., Armonk, NY). 114 cases were evaluated by ROC (Receiver operating characteristic) analysis in the breast-conserving surgery (BCS) and mastectomy groups. While only left lung volume (AUC: 0.74, 95% CI 0.61–0.87, p = 0.002) was significant in BCS cases, in cases with mastectomy, left lung volume (AUC: 0.81, 95% CI 0.69–0.94, p = 0.002) and lung/heart volume ratio (AUC: 0.83, 95% CI 0.70–0.96, p = 0.001) had a significant relationship with the relevance of heart doses. The cutoff point of 1.92 was selected for the lung/heart volume ratio for the mastectomized patients. Moreover, the cutoff point 1154 cc and 1208 cc was determined for the left lung volume for the BCS and mastectomized patients, respectively. Various cutoff points in left breast RT can be used to predict whether RT plans will meet QUANTEC (Quantitative Analysis of Normal Tissue Effects in the Clinic) heart dose limits. Evaluating only these few cutoff points before planning makes it possible to eliminate 70% of patients with BCS and 40% of patients with mastectomy from respiratory-controlled methods, which require time and effort. Patients with lung volume and lung/heart volume ratio smaller than the cutoff values can be considered primary candidates for heart-sparing techniques.
- Open Access
- 27 June 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-8
Stereotactic body radiation therapy for stage I medically operable non-small cell lung cancer
Stereotactic ablative body radiation therapy (SBRT) has emerged as the standard treatment for inoperable patients with stage I non-small cell lung cancer (NSCLC). In the current study, we retrospectively analyzed a medically operable patient cohort with stage I NSCLC who refused surgery and subsequently underwent SBRT. Overall survival (OS) and progression-free survival (PFS) were calculated. Between April 2014 and July 2020, 55 patients were enrolled to the study. Forty (72.7%) patients were male, with a mean age of 69.85 ± 4.65 years (range 59–78 years). ECOG performance status were 0 and 1, except for one case. At the time of analysis, 8 deaths were observed. Of these, 25% (n = 2) died due to cardiac events, 12.5% (n = 1) due to pulmonary causes, 12.5% (n = 1) due to lung cancer-related causes, and the cause of death was unknown for 50% (n = 4). The pulmonary causes and cardiac events were not associated with radiation-induced toxicity. The median survival time was 34 months, with a range of 12 to 44 months. 2-year OS and PFS were 97% and 98%, 3-year OS and PFS were 82% and 77%, respectively. Treatment with SBRT was well tolerated and no grade 3 and 4 treatment-related adverse events were observed. SBRT seems to be a well- tolerated and effective alternative for patients with operable early-stage NSCLC.
- 27 June 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-8
Open AccessStereotactic body radiation therapy for stage I medically operable non-small cell lung cancer
Stereotactic ablative body radiation therapy (SBRT) has emerged as the standard treatment for inoperable patients with stage I non-small cell lung cancer (NSCLC). In the current study, we retrospectively analyzed a medically operable patient cohort with stage I NSCLC who refused surgery and subsequently underwent SBRT. Overall survival (OS) and progression-free survival (PFS) were calculated. Between April 2014 and July 2020, 55 patients were enrolled to the study. Forty (72.7%) patients were male, with a mean age of 69.85 ± 4.65 years (range 59–78 years). ECOG performance status were 0 and 1, except for one case. At the time of analysis, 8 deaths were observed. Of these, 25% (n = 2) died due to cardiac events, 12.5% (n = 1) due to pulmonary causes, 12.5% (n = 1) due to lung cancer-related causes, and the cause of death was unknown for 50% (n = 4). The pulmonary causes and cardiac events were not associated with radiation-induced toxicity. The median survival time was 34 months, with a range of 12 to 44 months. 2-year OS and PFS were 97% and 98%, 3-year OS and PFS were 82% and 77%, respectively. Treatment with SBRT was well tolerated and no grade 3 and 4 treatment-related adverse events were observed. SBRT seems to be a well- tolerated and effective alternative for patients with operable early-stage NSCLC.
- 27 September 2022
- Published by Galenos Yayinevi in Medical Journal of Bakırkoy
- Vol. 18 (3) , 303-309
Can Temporal Muscle Thickness Be a New Prognostic Factor for De Novo Glioblastoma?
- 27 September 2022
- Published by Galenos Yayinevi in Medical Journal of Bakırkoy
- Vol. 18 (3) , 303-309
Can Temporal Muscle Thickness Be a New Prognostic Factor for De Novo Glioblastoma?
- Open Access
- 20 November 2021
- Published by Hindawi Limited in Case Reports in Oncological Medicine
- Vol. 2021, 1-14
Recurrent Solitary Fibrous Tumor in Intradural Extramedullary Space: Case Report and Review of the Literature
Solitary fibrous tumor/hemangiopericytoma (SFT/HPC) is a rare neoplasm arising from spindle cells and most commonly arising from pleura. Spinal SFT/HPC is a rare entity; hence, it is not on the top of the differential diagnosis list when a clinician faces a spinal lesion. In the review of the literature, there exist less than 50 case reports of intradural extramedullary SFT/HPC. Here, we present a 54-year-old female patient who underwent subtotal surgical excision of an intradural extramedullary spinal mass pathologically reported to be SFT/HPC and had symptomatic recurrence in the 3(rd) year of follow-up. Surgical intervention was unachievable and the patient was given 45 Gy to the surgical cavity followed by a 5.4 Gy boost to visible tumor with external radiotherapy. Patient reported significant relief of her symptoms. We aim to contribute to the formation of a treatment algorithm for this rare entity.
- 20 November 2021
- Published by Hindawi Limited in Case Reports in Oncological Medicine
- Vol. 2021, 1-14
Open AccessRecurrent Solitary Fibrous Tumor in Intradural Extramedullary Space: Case Report and Review of the Literature
Solitary fibrous tumor/hemangiopericytoma (SFT/HPC) is a rare neoplasm arising from spindle cells and most commonly arising from pleura. Spinal SFT/HPC is a rare entity; hence, it is not on the top of the differential diagnosis list when a clinician faces a spinal lesion. In the review of the literature, there exist less than 50 case reports of intradural extramedullary SFT/HPC. Here, we present a 54-year-old female patient who underwent subtotal surgical excision of an intradural extramedullary spinal mass pathologically reported to be SFT/HPC and had symptomatic recurrence in the 3(rd) year of follow-up. Surgical intervention was unachievable and the patient was given 45 Gy to the surgical cavity followed by a 5.4 Gy boost to visible tumor with external radiotherapy. Patient reported significant relief of her symptoms. We aim to contribute to the formation of a treatment algorithm for this rare entity.
- 1 October 2021
- Published by Academician Publishing
Kolorektal Cerrahi Hastalıklar
Sevgili meslektaşım;Günümüzde Türkçe olarak güncel kaynak kitap eksikliği iyi bilinen bir gerçektir. Bu açığı doldurabilmek amacı ile yola çıktık. Elinizdeki bu kaynak kitapta kolon ve rektumu ilgilendiren cerrahi hastalıklar 26 bölümde detaylı olarak ele alınmıştır. Kendi alanında uzman 25 kişiden oluşan yazar kadromuz bir yandan yoğun bir şekilde Corona Virüs hastalığına karşı mücadele verirken, değer yandan büyük özveride bulunarak kitabın hazırlanmasında büyük gayret göstermişlerdir.
- 1 October 2021
- Published by Academician Publishing
Kolorektal Cerrahi Hastalıklar
Sevgili meslektaşım;Günümüzde Türkçe olarak güncel kaynak kitap eksikliği iyi bilinen bir gerçektir. Bu açığı doldurabilmek amacı ile yola çıktık. Elinizdeki bu kaynak kitapta kolon ve rektumu ilgilendiren cerrahi hastalıklar 26 bölümde detaylı olarak ele alınmıştır. Kendi alanında uzman 25 kişiden oluşan yazar kadromuz bir yandan yoğun bir şekilde Corona Virüs hastalığına karşı mücadele verirken, değer yandan büyük özveride bulunarak kitabın hazırlanmasında büyük gayret göstermişlerdir.
- Open Access
- 27 August 2020
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10
Is Single Cord Irradiation Going to Be a New Standard for T1a Glottic Carcinoma?
Purpose and Objective: To evaluate the disease-free survival, overall survival, dosimetric, and voice handicap index (VHI) results of T1a glottic invasive squamous cell carcinoma (SCC) patients who underwent hypofractionated single vocal cord irradiation (HSVCI). Materials and Methods: The data of 18 patients with stage T1a glottic SCC were collected prospectively and analyzed retrospectively between July 2016 and July 2019. Patients were immobilized using a custom-fitted thermoplastic face and shoulder mask in hyperextension position. The CT scan was performed with 1-mm-thick slices. A planned target volume (PTV) margin of 3 mm was given to clinical target volume (CTV) in all directions, and 13 organs at risk were identified. Patients were prescribed a total of 5760–5808 cGy in 15–16 fractions. Patients had daily cone-beam computed tomography (CBCT), and the treatment was carried out with the physician. VHI test was applied to patients before and at the end of radiotherapy (RT) and 1, 2, 3, 4, and 6 months after the completion of RT. Results: Local control and overall survival rate is 100% for a median of 18 months (6–44 months) of follow-up. A patient was diagnosed with 2nd primary lung cancer and active treatment still continues. All patients completed the treatment within the scheduled time. Grade 1–2 dysphagia and dermatitis occurred in all patients, and no grade 3 and above side effects were observed. The mean values of VHI were 37.00, 39.83, 38.28, 17.17, 12.22, 8.56, and 6.06 at the beginning of RT, at the end of RT, and 1, 2, 3, 4, and 6 months after RT, respectively. Conclusion: Compared to surgery and conventional laryngeal radiotherapy, HSVCI is an alternative treatment method for T1a glottic cancer by reducing the treatment time to 3 weeks, facilitating recurrence treatment, and providing effective sound quality without compromising local control. Considering that ~80% of recurrences in glottic cancer occur within the first 2 years, 100% local control in a median of 18 months is extremely successful, but long-term follow-up is essential to observe possible late side effects.
- 27 August 2020
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10
Open AccessIs Single Cord Irradiation Going to Be a New Standard for T1a Glottic Carcinoma?
Purpose and Objective: To evaluate the disease-free survival, overall survival, dosimetric, and voice handicap index (VHI) results of T1a glottic invasive squamous cell carcinoma (SCC) patients who underwent hypofractionated single vocal cord irradiation (HSVCI). Materials and Methods: The data of 18 patients with stage T1a glottic SCC were collected prospectively and analyzed retrospectively between July 2016 and July 2019. Patients were immobilized using a custom-fitted thermoplastic face and shoulder mask in hyperextension position. The CT scan was performed with 1-mm-thick slices. A planned target volume (PTV) margin of 3 mm was given to clinical target volume (CTV) in all directions, and 13 organs at risk were identified. Patients were prescribed a total of 5760–5808 cGy in 15–16 fractions. Patients had daily cone-beam computed tomography (CBCT), and the treatment was carried out with the physician. VHI test was applied to patients before and at the end of radiotherapy (RT) and 1, 2, 3, 4, and 6 months after the completion of RT. Results: Local control and overall survival rate is 100% for a median of 18 months (6–44 months) of follow-up. A patient was diagnosed with 2nd primary lung cancer and active treatment still continues. All patients completed the treatment within the scheduled time. Grade 1–2 dysphagia and dermatitis occurred in all patients, and no grade 3 and above side effects were observed. The mean values of VHI were 37.00, 39.83, 38.28, 17.17, 12.22, 8.56, and 6.06 at the beginning of RT, at the end of RT, and 1, 2, 3, 4, and 6 months after RT, respectively. Conclusion: Compared to surgery and conventional laryngeal radiotherapy, HSVCI is an alternative treatment method for T1a glottic cancer by reducing the treatment time to 3 weeks, facilitating recurrence treatment, and providing effective sound quality without compromising local control. Considering that ~80% of recurrences in glottic cancer occur within the first 2 years, 100% local control in a median of 18 months is extremely successful, but long-term follow-up is essential to observe possible late side effects.